Navigating Zepbound: What Are the Available Doses and Your Personalized Path?

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Zepbound is manufactured in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. According to the Zepbound prescribing information, not all six function the same way in the label's logic. The 2.5 mg strength is described as being for treatment initiation and is not approved as a maintenance dosage. For weight reduction, the approved maintenance dosages are 5 mg, 10 mg, and 15 mg once weekly; for moderate-to-severe obstructive sleep apnea, they are 10 mg and 15 mg once weekly. The maximum dosage for all indications is 15 mg once weekly. Which of those applies to any individual is a prescriber's decision, not a menu choice — and this article explains the structure without becoming an instruction sheet.

The Six Strengths and What They Represent

All six strengths are supplied at the same volume, 0.5 mL per single-dose presentation, across the range from 2.5 mg to 15 mg. That uniformity is deliberate: the concentration changes, not the volume. The strengths exist so that a prescriber has granular options between the initiation strength and the maximum.

The label draws a sharp line between initiation strengths and maintenance strengths. Reading 2.5 mg as "the low-dose version of the treatment" is a misreading — the label says it is for treatment initiation and is not approved as maintenance. Similarly, 7.5 mg and 12.5 mg are not listed among the approved maintenance dosages for weight reduction; the label names 5 mg, 10 mg, and 15 mg for that indication. They function as intermediate steps within the escalation framework.

None of this is guidance you should apply to yourself. It is a description of how the labeled framework is organized, so that when your prescriber explains a plan, the vocabulary makes sense.

Two Indications, Two Maintenance Ranges

Zepbound holds two FDA-approved indications. The first is to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. The second is to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

The maintenance ranges differ between them. For weight reduction, the label names 5 mg, 10 mg, or 15 mg once weekly. For obstructive sleep apnea, it names 10 mg or 15 mg once weekly. That is a meaningful distinction: the indication you are being treated for shapes which part of the range is on the table, which is one reason a dosage decision cannot be lifted from a general article.

Worth keeping straight: Zepbound and Mounjaro both contain tirzepatide, but they are separate products with separate approvals. Mounjaro is approved for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. It has no weight-management indication. The dosage frameworks and labeled populations are not interchangeable.

Why the Label Escalates Gradually

The labeling describes a stepwise escalation framework rather than starting at a therapeutic dosage. There is a clinical reason for the design. Across the SURMOUNT program, the most common adverse events were gastrointestinal and were mostly mild to moderate, and they occurred primarily during dose escalation. Gradual escalation is a tolerability strategy.

The label also builds in a downward option: if a patient does not tolerate a maintenance dosage, a lower maintenance dosage is to be considered. That instruction is written to the prescriber. It reflects the reality that the highest dosage is not automatically the goal for every person, and that tolerability is part of the calculus, not an obstacle to be pushed through.

What the Dose-Response Data Actually Showed

In SURMOUNT-1, which ran 72 weeks in 2,539 adults with obesity or overweight without diabetes, mean weight change was −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg, compared with −3.1% with placebo. The label's second pivotal study reported −12.8% at 10 mg and −14.7% at 15 mg versus −3.2% with placebo, in a different population.

Two things follow. There is a dose-response relationship — higher studied dosages produced larger average reductions. But the increments narrow at the top of the range, and those figures are group means from populations with specific entry criteria. A trial average is not a forecast for an individual, and a higher number on the label is not automatically the right choice for a given person once tolerability, other conditions, and other medications enter the picture.

The Questions Your Prescriber Is Weighing

A dosage decision is not arithmetic. It draws on which indication is being treated, how you have tolerated the current dosage, what other medications you take — insulin and insulin secretagogues raise hypoglycemia considerations — and whether any of the label's warnings apply to you. Those warnings include severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions, and pulmonary aspiration during general anesthesia or deep sedation.

Zepbound also carries a boxed warning based on thyroid C-cell tumors observed in rats, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in people with known serious hypersensitivity to tirzepatide or any excipient. Pregnancy is a separate consideration: the label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm.

The most useful thing you can bring to that appointment is accurate information — a full medication list, your family history of thyroid cancer, any history of pancreatitis or gallbladder disease, and an honest account of how you have felt on your current regimen.

Where Compounded Tirzepatide Sits in This Picture

Compounded tirzepatide is a different regulatory category from Zepbound. It is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness, or quality before they are marketed. It is prepared by a licensed pharmacy pursuant to a prescription written for an individual patient. It is not a generic version of Zepbound or Mounjaro — neither has an approved generic.

That distinction matters when reading dose figures. The strengths and maintenance ranges described above come from Zepbound's FDA labeling and from the trials that supported it. A compounded preparation is not covered by that labeling, and any regimen involving one is determined by the prescriber who writes it, working with the dispensing pharmacy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What strengths does Zepbound come in?

Zepbound is supplied in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each in 0.5 mL single-dose presentations. The label describes the 2.5 mg strength as being for treatment initiation and states it is not approved as a maintenance dosage. The maximum dosage for all indications is 15 mg injected subcutaneously once weekly.

Which dosages are approved for maintenance?

It depends on the indication. For weight reduction, the Zepbound label names 5 mg, 10 mg, or 15 mg once weekly as the recommended maintenance dosages. For moderate-to-severe obstructive sleep apnea in adults with obesity, it names 10 mg or 15 mg once weekly. The 2.5 mg strength is not an approved maintenance dosage for either indication.

Is a higher dosage always more effective?

SURMOUNT-1 showed a dose-response relationship, with mean weight changes of −15.0%, −19.5%, and −20.9% at the three doses studied versus −3.1% with placebo over 72 weeks. But those are group averages, the increments narrow toward the top of the range, and tolerability matters. The label directs that a lower maintenance dosage be considered if a patient does not tolerate one.

Are Zepbound and Mounjaro dosed the same way?

They both contain tirzepatide, but they are separate FDA-approved products with separate labeling and separate indications. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is approved for glycemic control in type 2 diabetes and has no weight-management indication. Do not transfer one label's framework to the other.

Who decides which dosage is right for me?

Your prescriber, using your indication, your tolerability, your other medications and diagnoses, and the label's warnings and contraindications. Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in those with known serious hypersensitivity to tirzepatide or any excipient. Bring your full history to that conversation.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.